Enanta Pharmaceuticals Inc (ENTA) Increases Again; Strong Momentum for Buyers

September 17, 2017 - By Richard Conner

Investors sentiment decreased to 1.47 in Q4 2016. Its down 0.06, from 1.53 in 2016Q3. It dived, as 13 investors sold Enanta Pharmaceuticals Inc shares while 36 reduced holdings. 23 funds opened positions while 49 raised stakes. 12.65 million shares or 0.84% less from 12.75 million shares in 2016Q3 were reported.
Moreover, Walleye Trading Limited Liability Corp has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 9,500 shares. Envestnet Asset Management Inc accumulated 0% or 8,783 shares. Moreover, Adams Diversified Equity Fund has 0.05% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Blackrock Japan Com Ltd accumulated 430 shares. Wells Fargo And Mn invested in 11,720 shares. Dupont Mngmt Corp holds 30,099 shares. Eqis Capital Management has invested 0.07% of its portfolio in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Guggenheim Cap Ltd Limited Liability Company reported 0% stake. 102,525 are owned by Principal Fincl Grp Inc. California-based Wall Street Assoc has invested 0.23% in Enanta Pharmaceuticals Inc (NASDAQ:ENTA). Qs Investors Ltd Liability Company reported 78,341 shares or 0.02% of all its holdings. Manufacturers Life Insur The has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 11,068 shares. Texas Permanent School Fund, Texas-based fund reported 10,135 shares. Prudential holds 48,928 shares or 0% of its portfolio. Moreover, Geode Ltd Company has 0% invested in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) for 132,584 shares.

The stock of Enanta Pharmaceuticals Inc (NASDAQ:ENTA) is a huge mover today! The stock increased 4.55% or $1.96 on September 15, reaching $45.06. About 355,589 shares traded or 88.35% up from the average. Enanta Pharmaceuticals Inc (NASDAQ:ENTA) has risen 40.91% since September 17, 2016 and is uptrending. It has outperformed by 24.21% the S&P500.
The move comes after 8 months positive chart setup for the $860.21 million company. It was reported on Sep, 17 by Barchart.com. We have $48.66 PT which if reached, will make NASDAQ:ENTA worth $68.82 million more.

Analysts await Enanta Pharmaceuticals Inc (NASDAQ:ENTA) to report earnings on November, 20. They expect $1.94 earnings per share, up 2,255.56 % or $2.03 from last year’s $-0.09 per share. ENTA’s profit will be $37.04M for 5.81 P/E if the $1.94 EPS becomes a reality. After $-0.44 actual earnings per share reported by Enanta Pharmaceuticals Inc for the previous quarter, Wall Street now forecasts -540.91 % EPS growth.

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Ratings Coverage

Among 5 analysts covering Enanta Pharmaceuticals Inc (NASDAQ:ENTA), 3 have Buy rating, 1 Sell and 1 Hold. Therefore 60% are positive. Enanta Pharmaceuticals Inc had 14 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was upgraded by JMP Securities to “Market Outperform” on Tuesday, July 11. The stock has “Overweight” rating by JP Morgan on Tuesday, August 9. The firm has “Mkt Outperform” rating by JMP Securities given on Friday, October 23. As per Thursday, April 28, the company rating was downgraded by JMP Securities. The rating was downgraded by Barclays Capital to “Underweight” on Friday, October 23. The firm has “Neutral” rating given on Tuesday, August 8 by Robert W. Baird. Zacks downgraded Enanta Pharmaceuticals Inc (NASDAQ:ENTA) on Friday, August 7 to “Buy” rating. TheStreet downgraded the shares of ENTA in report on Saturday, August 8 to “Buy” rating.

More notable recent Enanta Pharmaceuticals Inc (NASDAQ:ENTA) news were published by: Seekingalpha.com which released: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Fiscal Q3 2017 Results …” on August 08, 2017, also Seekingalpha.com with their article: “Enanta Pharmaceuticals’ (ENTA) CEO Jay Luly on Q2 2017 Results – Earnings Call …” published on May 08, 2017, Seekingalpha.com published: “Enanta: Half Cash, All Upside” on February 28, 2017. More interesting news about Enanta Pharmaceuticals Inc (NASDAQ:ENTA) were released by: Seekingalpha.com and their article: “Enanta To Retain Momentum On The Back Of Upcoming FDA Decision” published on July 10, 2017 as well as Seekingalpha.com‘s news article titled: “Biotech Forum Daily Digest: Fallout From The ACA Repeal Debacle. Spotlight On …” with publication date: March 27, 2017.

Enanta Pharmaceuticals, Inc. is a research and development-focused biotechnology company. The company has market cap of $860.21 million. The Firm uses chemistry-driven approach and drug discovery solutions to create small molecule drugs for the treatment of viral infections and liver diseases. It currently has negative earnings. The Company’s research and development programs are focused on three disease targets: non-alcoholic steatohepatitis / primary biliary cholangitis (PBC), respiratory syncytial virus (RSV) and hepatitis B virus (HBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.